semaglutide size Biosimilar and Generic Market Size, Share and Latest Trends 2026 to 2035 GLP-1 Weight Loss Statistics 2026:
Description
In contrast, WCand by extension, the waist-to-height ratio (WHtR)serves as a more accurate surrogate marker for central obesity and cardiometabolic risk, especially in individuals with T2DM and insulin resistance

The rollout of these drugs is going to be taking a long time given the cost and capacity constraints, Mr

Additionally, Goldman Sachs projects the broader market for anti-obesity drugs including Zepbound could to hit $100 billion per year by 2030, a 16-fold increase from 2023 levels

Further research is needed to confirm their therapeutic efficacy in humans

Breakthrough obesity drugs are effective but raise questions

There is no need to double up
